ArticleBlood2018
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 46 citations in OpenAlex.
- Luteolin Protects Against Noise-Induced Hearing Loss via Mitigating Oxidative Stress and Apoptosis, With Potential Regulation of the EGR1/SPRY4 Axis.CNS neuroscience & therapeutics · 2026Article
- The roles of non-coding RNAs (ncRNAs) in the function of leukemic stem cells (LSCs): a comprehensive review.Discover oncology · 2025Review
- Review
- Human liver progenitor-like cells-derived extracellular vesicles promote liver regeneration during acute liver failure.Cell biology and toxicology · 2024Article
- Article
- Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease.Nature communications · 2024Article
- miR-181a plays the tumor-suppressor role in chronic myeloid leukemia CD34Cellular and molecular life sciences : CMLS · 2023Article
- Progenitor-like cell type of an MLL-EDC4 fusion in acute myeloid leukemia.Blood advances · 2023Article
- Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells.Nature communications · 2023Article
- Review
- mTORC2 Is Activated under Hypoxia and Could Support Chronic Myeloid Leukemia Stem Cells.International journal of molecular sciences · 2023Article
- Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2022Observational
- Biological Therapies in the Treatment of Cancer-Update and New Directions.International journal of molecular sciences · 2021Review
- Serine 26 in Early Growth Response-1 Is Critical for Endothelial Proliferation, Migration, and Network Formation.Journal of the American Heart Association · 2021Article
- Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?International journal of molecular sciences · 2021Review
- Article
- LncRNA Lnc-APUE is Repressed by HNF4Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Article
- Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells.Nature communications · 2021Article
- Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.International journal of molecular sciences · 2021Review
Corrections and comments
- Commented on by
Authors and funding
17 authors at 5 institutions in 2 countries.
Francesca PellicanoPaul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Laura ParkPaul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Lisa E M HopcroftPaul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0002-7022-1322
Mansi M ShahPaul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Lorna JacksonPaul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0002-6023-9908
Mary T ScottPaul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0002-7177-6960
Cassie J ClarkePaul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0003-2232-1609
Amy SinclairPaul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Sheela A AbrahamPaul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0003-4114-138X
Alan HairPaul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
G Vignir HelgasonPaul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0003-1616-132X
Mark Aspinall-O'DeaStem Cell and Leukaemia Proteomics Laboratory, Faculty Institute of Cancer Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.
Ravi BhatiaDivision of Hematology and Oncology, School of Medicine, The University of Alabama at Birmingham, Birmingham, AL.
Gustavo LeoneHollings Cancer Center, Medical University of South Carolina, Charleston, SC; and.
Kamil R KrancMRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0001-7547-4989
Anthony D WhettonStem Cell and Leukaemia Proteomics Laboratory, Faculty Institute of Cancer Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.ORCID 0000-0002-1098-3878
Tessa L HolyoakePaul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
University of Glasgow · GBManchester Academic Health Science Centre · GBMedical University of South Carolina · USMRC Centre for Regenerative Medicine · GBUniversity of Alabama at Birmingham · US
Funding
Resistance of CML stem cells to STI571 (Gleevec)R01CA095684 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BHATIA, RAVI · 2003 to 2017
$4.6MTumor Suppressor Roles of E2F7 & E2F8 in Hepatocellular Carcinoma (HCC)R01CA121275 · NCI · OHIO STATE UNIVERSITY · PI LEONE, GUSTAVO WALTER · 2008 to 2018
$3.1MBiotechnology and Biological Sciences Research Council BB/F016050/1Cancer Research UK 11008Cancer Research UK 14633Cancer Research UK 26787Chief Scientist OfficeMedical Research Council MR/K500847/1Medical Research Council MR/N00583X/1Medical Research Council MR/P010008/1NCI NIH HHS R01 CA095684NCI NIH HHS R01 CA121275
Abstract
Chronic myeloid leukemia (CML) stem/progenitor cells (SPCs) express a transcriptional program characteristic of proliferation, yet can achieve and maintain quiescence. Understanding the mechanisms by which leukemic SPCs maintain quiescence will help to clarify how they persist during long-term targeted treatment. We have identified a novel BCR-ABL1 protein kinase-dependent pathway mediated by the upregulation of
Indexed as
Gene Expression Regulation, LeukemicUp-RegulationAnimalsCell ProliferationCell SurvivalE2F1 Transcription FactorEarly Growth Response Protein 1FemaleHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMice, KnockoutMicroRNAsNeoplasm ProteinsNeoplastic Stem CellsRNA, NeoplasmE2F1 protein, humanE2F1 Transcription FactorEarly Growth Response Protein 1EGR1 protein, humanMicroRNAsMIRN183 microRNA, humanNeoplasm ProteinsRNA, Neoplasm
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.